It is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Alpha-Glucosidase inhibitor
Miglitol is a desoxynojirimycin derivative. Miglitol does not enhance insulin secretion. The antihyperglycemic action of Miglitol results from a reversible inhibition of membrane bound intestinal α-glucoside hydrolase enzymes. Membrane-bound intestinal α- glucosidases hydrolyze oligosaccharides and disaccharides to glucose and other monosaccharides in the brush border of the small intestine. In diabetic patients, this enzyme inhibition results in delayed glucose absorption and lowering of postprandial hyperglycemia. As a consequence of plasma glucose reduction, Miglitol reduce levels of glycosylated hemoglobin.
Unlike sulfonylureas or insulin,an overdose of It tablets will not result in hypoglycemia. An overdose may result in transient increases in flatulence,diarrhea,and abdominal discomfort. Because of the lack of extra-intestinal effects seen with It, no serious systemic reactions are expected in the event of an overdose.
The mean Cmax and AUC values for glyburide & metformin decrease when co-administered with Miglitol. Miglitol may significantly reduce the bioavailability of ranitidine and propranolol. Intestinal adsorbents (e.g.charcoal) and digestive enzyme preparations containing carbohydrate-splitting enzymes (e.g.amylase, pancreatin) may reduce the effect of Miglitol and should not be taken concomitantly.
It Tablets are contraindicated in patients with: ? Diabetic ketoacidosis ? Inflammatory bowel disease,colonic ulceration,or partial intestinal obstruction, and in patients predisposed to intestinal obstruction ? Chronic intestinal diseases associated with marked disorders of digestion or absorption,or with conditions that may deteriorate as a result of increased gas formation in the intestine ? Hypersensitivity to the drug or any of its components.
Side Effects Abdominal pain or discomfort,diarrhoea,flatulence,skin rash
Category B: Either animal-reproduction studies have not demonstrated a fetal risk but there are no controlled studies in pregnant women or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is no evidence of a risk in later trimesters).Nursing Mothers Miglitol has been shown to be excreted in human milk to a very small degree. Total excretion into milk accounted for 0.02% of a 100 mg maternal dose. The estimated exposure to a nursing infant is approximately 0.4% of the maternal dose. Although the levels of miglitol reached in human milk are exceedingly low,it is recommended that It not be administered to a nursing woman.
Overdose of Miglitol will not result in hypoglycemia. An overdose may result in transient increases in flatulence, diarrhea, and abdominal discomfort. Because of the lack of extra-intestinal effects seen with Miglitol, no serious systemic reactions are expected in the event of an overdose.
Store in a cool and dry place. Protect from light.
.png&w=384&q=75)